Kymera Therapeutics, Inc. (KYMR)
108.69
+3.91
(+3.73%)
USD |
NASDAQ |
Oct 19, 13:00
Kymera Therapeutics Enterprise Value : 8.062B for Oct. 16, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 16, 2026 | 8.062B |
| October 15, 2026 | 8.340B |
| October 14, 2026 | 8.232B |
| October 13, 2026 | 8.219B |
| October 12, 2026 | 8.666B |
| October 09, 2026 | 8.693B |
| October 08, 2026 | 8.436B |
| October 07, 2026 | 8.358B |
| October 06, 2026 | 8.161B |
| October 05, 2026 | 8.482B |
| October 02, 2026 | 8.278B |
| October 01, 2026 | 8.504B |
| September 30, 2026 | 8.642B |
| September 29, 2026 | 8.537B |
| September 28, 2026 | 8.660B |
| September 25, 2026 | 8.656B |
| September 24, 2026 | 8.975B |
| September 23, 2026 | 8.947B |
| September 22, 2026 | 9.493B |
| September 21, 2026 | 9.129B |
| September 18, 2026 | 9.136B |
| September 17, 2026 | 9.196B |
| September 16, 2026 | 9.018B |
| September 15, 2026 | 8.755B |
| September 14, 2026 | 8.878B |
| Date | Value |
|---|---|
| September 11, 2026 | 8.905B |
| September 10, 2026 | 9.074B |
| September 09, 2026 | 8.944B |
| September 08, 2026 | 9.030B |
| September 04, 2026 | 9.106B |
| September 03, 2026 | 9.097B |
| September 02, 2026 | 9.209B |
| September 01, 2026 | 9.244B |
| August 31, 2026 | 9.224B |
| August 28, 2026 | 9.169B |
| August 27, 2026 | 9.341B |
| August 26, 2026 | 9.782B |
| August 25, 2026 | 9.872B |
| August 24, 2026 | 9.409B |
| August 21, 2026 | 9.306B |
| August 20, 2026 | 9.446B |
| August 19, 2026 | 9.927B |
| August 18, 2026 | 9.436B |
| August 17, 2026 | 9.439B |
| August 14, 2026 | 9.106B |
| August 13, 2026 | 8.860B |
| August 12, 2026 | 8.828B |
| August 11, 2026 | 8.463B |
| August 10, 2026 | 8.377B |
| August 07, 2026 | 8.289B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Intellia Therapeutics, Inc. | 1.235B |
| Twist Bioscience Corp. | 8.247B |
| Beam Therapeutics, Inc. | 1.518B |
| Arrowhead Pharmaceuticals, Inc. | 7.664B |
| Oncolytics Biotech, Inc. | 58.41M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -61.21M |
| Revenue (Quarterly) | 65.00M |
| Total Expenses (Quarterly) | 126.21M |
| EPS Diluted (Quarterly) | -0.6235 |
| Gross Profit Margin (Quarterly) | 96.88% |
| Profit Margin (Quarterly) | -94.17% |
| Earnings Yield | -2.98% |
| Normalized Earnings Yield | -2.954 |